Anthem Biosciences IPO is one of the most anticipated offerings in the pharmaceutical sector this year. With a total issue size of ₹3,395 crore, the IPO will be a 100% offer for sale (OFS), meaning no new shares will be issued. Instead, existing shareholders will be offloading their stake. There is no fresh issue component in this public offering.

While the IPO dates, price band, and share allotment schedule have not yet been announced, investor interest remains high due to the company’s strong financials and reputation in the CRAMS (Contract Research and Manufacturing Services) space.

JM Financial has been appointed as the book-running lead manager (BRLM) for the Anthem Biosciences IPO, responsible for managing the issue and guiding institutional participation. Meanwhile, Kfin Technologies will act as the IPO registrar, handling application processing, allotment, and investor support.

With robust fundamentals, global clientele, and strong profit margins, Anthem Biosciences Limited is positioning itself as a high-potential listing. Investors are advised to stay updated as the company announces further details like the price band, listing date, and GMP (Grey Market Premium) in the coming weeks.

Refer to  Anthem Biosciences IPO DRHP for detailed information.

Anthem Biosciences IPO Reservation

Note: The exact reservation percentages will be confirmed in the Red Herring Prospectus (RHP) once it’s released.

About Anthem Biosciences Limited

The Anthem Biosciences IPO marks a significant milestone for one of India’s leading contract research and manufacturing services (CRAMS) providers. Established in 2007 and headquartered in Bengaluru, Anthem Biosciences Limited has built a strong reputation in the global pharmaceutical and biotechnology sectors. As the company gears up for the Anthem Biosciences IPO, investors are turning their attention to its robust business model, global partnerships, and expansion plans.

Anthem operates across a wide spectrum of services, including custom chemical synthesis, fermentation-based production, high-potency APIs, biocatalysis, and advanced analytical services. Its manufacturing infrastructure includes GMP-compliant facilities, kilo labs, and pilot plants, spread across a large integrated campus in Bengaluru. These plants cater to domestic and global clients, aligning with regulatory standards such as US FDA, EMA, and PMDA.

A major attraction of the Anthem Biosciences IPO is the company’s strong foothold in R&D-driven manufacturing, with a focus on both innovator and generic markets. It supplies to top-tier pharmaceutical companies across the US, Europe, and Asia, with a diverse product pipeline that includes biologics, enzymes, and specialty chemicals.

With the launch of the Anthem Biosciences IPO, the company aims to provide liquidity to existing shareholders (as the IPO is a full Offer for Sale) while also strengthening its brand in capital markets. Investors looking for exposure to India’s high-growth biopharma and life sciences sector will find the Anthem Biosciences IPO a promising opportunity backed by innovation, global compliance, and scalability.

The Anthem Biosciences IPO is not just a capital market event—it’s a gateway into the future of high-value pharmaceutical manufacturing in India.

Company Financials

Anthem Biosciences Limited Financial Information (Restated)

Insight: Anthem Biosciences IPO is backed by strong EBITDA and PAT margins, consistent earnings, and a steadily growing asset base — all signs of operational strength and financial stability.